PACKAGE LEAFLET. Efavirenz 600 mg tablet WHOPAR part 3 April 2010 (Hetero Labs Ltd), HA399 Section 6 updated: May 2016 Section 2 updated: July 2018

Similar documents
PATIENT INFORMATION LEAFLET

Efavirenz Mylan 600 mg Film-coated Tablets

WHO-PQ RECOMMENDED PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

INTELENCE etravirine. What is in this leaflet. Before you take INTELENCE. What INTELENCE is used for. When you must not use it:

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUOVIR N * (Lamivudine/Zidovudine /Nevirapine 150/ 300/200 mg)

PATIENT INFORMATION LEAFLET

B. PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

ATORIS 10, 20, 40 mg film-coated tablets

PATIENT INFORMATION LEAFLET

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

B. PATIENT INFORMATION LEAFLET

Package leaflet: Information for the user. EDURANT 25 mg film-coated tablets rilpivirine

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

What is in this leaflet

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET. Lamivudine/Zidovudine 150/300 mg Tablets WHOPAR part 3 04/2009, version 1.0 Section 6 updated: June 2017 (Mylan Lab.

Package leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin

Package leaflet: Information for the user. Entecavir Alvogen 0,5 mg filmomhulde tabletten Entecavir Alvogen 1 mg filmomhulde tabletten Entecavir

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient. SIRTURO 100 mg tablets Bedaquiline

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. ZEPATIER 50 mg of elbasvir and 100 mg of grazoprevir

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER. Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride)

Package leaflet: Information for the patient. Felodipin AstraZeneca 10 mg prolonged-release tablets. felodipine

XYZAL 5 MG FILM-COATED TABLET

Patient Information Entecavir Tablets (en-tek-ah-veer)

PACKAGE LEAFLET: INFORMATION FOR THE USER

Nevirapine 200mg Tablet WHOPAR part 3 May 2005 Updated: May 2016 PACKAGE LEAFLET

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. Lercanidipine 10 mg film-coated tablets Lercanidipine 20 mg film-coated tablets

Lopinavir/Ritonavir 200 mg/50 mg Tablets (Hetero Labs Ltd), HA492. WHOPAR Part 3 February 2014 PACKAGE LEAFLET. Page 1 of 9

Consumer Medicine Information. Read all of this leaflet carefully before you start taking this medicine.

PATIENT INFORMATION LEAFLET

Abacavir Sulfate, Lamivudine and Zidovudine Tablets WHOPAR Part 3 05/2009, version mg/150mg/300mg (Ranbaxy Laboratories Ltd), HA324

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam)

Package leaflet: Information for the user

BOSLEER CONSUMER MEDICINE INFORMATION

Zofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

PATIENT INFORMATION LEAFLET

Otezla (apremilast) film coated tablets

PATIENT INFORMATION LEAFLET

Package Leaflet: Information for the User Zofran tablets 4 mg and 8 mg ondansetron (as hydrochloride dihydrate)

PATIENT INFORMATION LEAFLET

Efavirenz, stavudine and lamivudine

PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Bluefish 1000 mg film-coated tablets Valaciclovir

Patient Information SUSTIVA (sus-tee-vah) (efavirenz) capsules. (efavirenz) tablets

Package leaflet: Information for the patient. Symkevi 100 mg/150 mg film-coated tablets tezacaftor/ivacaftor

Pyrazinamide 500 mg Tablets (Macleods Pharmaceuticals Ltd), TB243. WHOPAR part 3 April 2014 Section 6 updated: May 2014 PACKAGE LEAFLET.

Package leaflet: Information for the user. Levonorgestrel 1.5 mg Tablet. levonorgestrel

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

WHOPAR Part 3 March Zinc (as sulfate monohydrate) 20 mg Tablets (Macleods Pharmaceuticals Ltd), DI005 PACKAGE LEAFLET.

How Entecavir GH Works

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

NORVASC 5 mg and 10 mg tablets

GlaxoSmithKline Research Triangle Park, NC the ViiV Healthcare group of companies. All rights reserved. ZGN:XPI

B. PATIENT INFORMATION LEAFLET

TIVICAY 50 mg film-coated tablets Dolutegravir Consumer Medicine Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. PIFELTRO doravirine tablets

PATIENT INFORMATION LEAFLET

TIVICAY 50 mg film-coated tablets

Package leaflet: Information for the patient. Atorvastatin Krka 40 mg film-coated tablets. Atorvastatin

Package leaflet: Information for the patient. Selincro 18 mg film-coated tablets nalmefene

PATIENT INFORMATION LEAFLET

Package Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets

PATIENT INFORMATION LEAFLET AMLOC RANGE

PATIENT INFORMATION LEAFLET

2 What you need to know before you take Naramig

PREZISTA. What is in this leaflet. Before you take PREZISTA. What PREZISTA is used for. darunavir. When you must not use it:

Package leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

PATIENT INFORMATION LEAFLET

Who should not take STRIBILD? Do not take STRIBILD if you also take a medicine that contains:

Package leaflet: Information for the user. Zerit 20 mg hard capsules Stavudine

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

Package leaflet: Information for the patient. Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone

Package leaflet: Information for the patient. Moventig 12.5 mg film-coated tablets Moventig 25 mg film-coated tablets. naloxegol

Onglyza CONSUMER MEDICINE INFORMATION

Transcription:

PACKAGE LEAFLET Page 1 of 7

PACKAGE LEAFLET: INFORMATION FOR THE USER Estiva 600 (Efavirenz 600 mg Tablets) * Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. In this leaflet: 1. What Estiva - 600 is and what it is used for 2. Before you take Estiva - 600 3. How to take Estiva - 600 4. Possible side effects 5. How to store Estiva - 600 6. Further information 1. WHAT ESTIVA - 600 IS AND WHAT IT IS USED FOR Estiva - 600 belongs to a class of antiretroviral medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is an antiretroviral medicine that fights human immunodeficiency virus (HIV) infection by reducing the amount of the virus in the blood. Estiva - 600 is used in antiretroviral combination therapy for the treatment of HIV infection. Estiva - 600 reduces the amount of HIV virus in your body and keeps it at a low level. It also increases CD4 cell counts. CD4 cells are a type of white blood cell that plays an important role in maintaining a healthy immune system to help fight infection. Response to treatment with Estiva - 600 varies between patients. Your doctor or health care provider will be monitoring the effectiveness of your treatment. Estiva - 600 may improve your condition, but it is not a cure for your HIV infection. HIV infection is a disease spread by contact with blood or sexual contact with an infected individual. Treatment with Estiva - 600 has not been shown to eliminate the risk of passing HIV infection on to others by sexual contact or by blood transfer. Therefore, you must continue to take appropriate precautions to avoid giving the virus to others. During your treatment, other infections linked to your weakened immunity (opportunistic infections) may arise. These will require specific and sometimes preventive treatment. 2. BEFORE YOU TAKE ESTIVA - 600 Do not take Estiva - 600 if: - you are allergic (hypersensitive) to efavirenz or any of the other ingredients of Estiva - 600 (see section 6, What Estiva - 600 contains); - if you are currently taking St. John s wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety) * Trade names are not prequalified by WHO. This is under local DRA responsibility. Throughout this WHOPAR the proprietary name is given as an example only. Page 2 of 7

Take special care with Estiva - 600 Before using this medicine, you should have told your doctor or health care provider: - if you suffer from liver disease (such as hepatitis); - about past or present medical problems including allergies, seizures, mental illness, or substance or alcohol abuse. A mild-to-moderate skin rash commonly develops in the first two weeks after starting with Estiva - 600, this usually resolves within 4 weeks of the beginning of treatment; in case of a progression to a severe rash you need to tell your doctor or health care provider immediately and Estiva - 600 may have to be discontinued. Following the start of Estiva - 600 central nervous system side effects are very common, usually starting in the first week of treatment. These may include dizziness, confusion, insomnia, somnolence, impaired concentration and abnormal dreaming. Other side effects are amnesia, hallucinations, euphoria, depression, suicidal ideation or psychosis (see section 4). These usually resolve within four weeks of the start of treatment. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-hiv treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. If you notice any symptoms of infection, please inform your doctor or health care provider immediately. You will need to take Estiva - 600 every day. This medicine helps to control your condition, but it is not a cure for HIV infection. You may continue to develop other infections and other illnesses associated with HIV disease. You should keep in regular contact with your doctor or health care provider. Do not stop taking your medicine without first talking to your doctor or health care provider. Taking other medicines Please tell your doctor, health care provider or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. These may affect the action of Estiva - 600, or Estiva - 600 may affect their action. Estiva - 600 must not be taken with herbal preparations containing St John s wort (Hypericum perforatum) Estiva - 600 should not be taken with the following agents: astemizole, cisapride, terfenadine, midazolam, triazolam, pimozide, bepridil and ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine). Taking these medicines with Estiva - 600 may cause serious and / or life-threatening side effects. Estiva 600 should not be used as part of a triple combination regimen consisting of efavirenz, didanosine and tenofovir because of inferior efficacy compared to other combination regimens; Estiva - 600 may also interact with the following medicines and may make any side effects worse or may impact on the either agent s efficacy: - amprenavir, atazanavir, darunavir, indinavir, lopinavir, maraviroc, nelfinavir, ritonavir, saquinavir and tipranavir (antiviral agents). - methadone, buprenorphine (used to treat severe pain or opioid dependency); - clarithromycin, rifabutin or rifampicin (antibacterials/antituberculotics), - atorvastatin, pravastatin, or simvastatin (lipid-lowering medicines, also called statins) - hormonal contraceptives such as birth control pills, an injected contraceptive or a contraceptive implant. Therefore, you should employ an alternative contraceptive method such as barrier contraception (e.g. condoms), if you are taking Estiva - 600 (see also pregnancy and breast-feeding ).. - voriconazole, itraconazole, posaconazole (antifungals) - amodiaquine /artesunate, quinine, lumefantrine, halofantrine, artemisine (antimalarials) Page 3 of 7

- carbamazepine, phenytoin (anticonvulsants) - diltiazem, verapamil, felodipine, nifedipine, nicardipine (calcium channel blocker) - tacrolimus, cyclosporine, sirolimus (immunosuppressants) - warfarin (medicine for prophylaxis of blood clots) Taking Estiva - 600 with food and drink Estiva - 600 should be taken on an empty stomach or with a low-fat meal. Pregnancy Inform your doctor immediately if you are pregnant or intend to become pregnant. If you are pregnant, you should take Estiva - 600 only if you and your doctor decide it is clearly needed. Malformations have been seen in foetuses from animals and in newborns of women treated with efavirenz during pregnancy; therefore, pregnancy should be avoided in women receiving Estiva - 600. If you are a woman receiving Estiva - 600, a reliable form of barrier contraception (for example a condom) should always be used, with other methods of contraception including oral (pill) or other hormonal contraceptives (for example implant, injection). Breastfeeding If a mother wants to breastfeed her baby, her doctor or healthcare provider should be asked for advice on the risks and benefits. Treatment of mother and/or child with medicines may be needed. Generally it is recommended that HIV-infected women should not breast-feed their infants because of the possibility that the baby may be infected with HIV through the breast milk. Driving and using machines Dizziness, impaired concentration, and drowsiness have been reported during treatment with Estiva - 600. If you experience these symptoms you should avoid potentially hazardous tasks such as driving or operating machinery. Estiva - 600 contains lactose If you have been told by your health care provider that you have an intolerance to some sugars, contact your health care provider before taking this medicinal product. 3. HOW TO TAKE ESTIVA - 600 Always take Estiva - 600 exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure. The usual daily dose for adults and adolescents weighing 40 kg or more is 600 mg, given once daily. Children Since Estiva - 600 can not be divided, Estiva - 600 is not suitable for patients whose body weight is less than 40 kg. In these cases another formulation should be used, e.g. a tablet/capsule containing less efavirenz, or an oral solution. Efavirenz is not recommended for use in children weighing less than 13 kg due to a lack of data on safety and efficacy. Estiva - 600 should be taken on an empty stomach, e.g. in the evening before going to bed. Estiva - 600 will always be taken in combination with other antiretroviral medication; please make sure to follow also the instructions within the supplied package leaflet of the other products. Page 4 of 7

If you take more Estiva - 600 than you should If you take too much Estiva - 600 consult your doctor or local first aid hospital. If you forget to take Estiva - 600 Try not to miss a dose. If you do miss a dose, take the next dose as soon as possible. However, when the next regular dose is due within 12 hours, then simply take your normal next dose at its due time. Do not double the dose. If you stop taking Estiva - 600 Do not stop taking Estiva - 600 unless you experience serious side effects or your doctor has told you to. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The virus may then become harder to treat. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. POSSIBLE SIDE EFFECTS Like all medicines, Estiva - 600 can cause side effects, although not everybody gets them. The most frequently reported adverse reactions associated with Estiva - 600 in combination with other anti-hiv medicines include skin rash, dizziness, nausea, headache and fatigue. The most notable unwanted effects are skin rash and nervous system symptoms that include dizziness, insomnia, somnolence (drowsiness), impaired concentration and abnormal dreaming. You should consult your doctor if you have a rash, since some rashes may be serious; however, most cases of rash disappear without any change to your treatment with Estiva - 600. Rash was more common in children than in adults treated with Estiva - 600. Very commonly reported (greater than 1 in every 10 patients treated) side effects are rash, and changes in fat metabolism as shown by increase in lipid levels in the blood. Commonly reported (greater than 1 in every 100 patients treated) side effects are dizziness, insomnia, somnolence, impaired concentration, abnormal dreaming, headache, fatigue, anxiety, depression, disturbed liver function as detected by elevation of liver enzymes in blood, pruritus, abdominal pain, diarrhoea, nausea, vomiting. The following side effects are uncommon (between 1 in 1,000 and 1 in 100 patients treated): psychosis (mental state with severely impaired thought and perception). The likelihood is increased in those with a history of psychiatric disease. Affect lability, aggression, abnormal thoughts, nervousness, forgetfulness, problems with coordination, vertigo, confusion, fits (seizures), suicidal thoughts, acute hepatitis, acute pancreatitis, blurred vision, breast enlargements in males (gynaecomastia), and allergic reaction (hypersensitivity) that may cause severe skin reactions (erythema multiforme). Side effects reported with an unknown frequency: coordination and balance disturbances, flushing; ringing or other persistent noise in the ears (tinnitus), and tremor (shaking). Combination antiretroviral therapy may cause hyperlipidaemia (increased fats in the blood), resistance to insulin, raised sugar and lactic acid in the blood. Moreover, it may cause a condition called lactic acidosis, which is a build up of lactic acid in the body that can cause dehydration and coma which have been reported on rare occasions in patients taking certain antiretrovirals (so-called NRTIs). Deep, rapid breathing, drowsiness, and non specific symptoms such as nausea, vomiting and stomach pain, may indicate the development of lactic acidosis. Page 5 of 7

Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution. These may include loss of fat from legs, arms and face, increased fat in the abdomen (belly) and other internal organs, breast enlargement and fatty lumps on the back of the neck ('buffalo hump'). The cause and long-term health effects of these conditions are not known at this time. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist. 5. HOW TO STORE ESTIVA - 600 Keep out of the reach of children. Store below 30ºC, protected from light and moisture. Do not use Estiva - 600 after the expiry date which is stated on the label. The expiry date refers to the last day of that month. Do not use Estiva - 600 if you notice any visual signs of deterioration. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. 6. FURTHER INFORMATION What Estiva - 600 contains The active ingredient is 600 mg efavirenz. Tablet core: croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate. Film-coating: Hypromellose, iron oxide yellow, titanium dioxide and macrogol/peg 400. What Estiva - 600 looks like and contents of the pack Yellow, capsular shaped, film-coated tablets, debossed with H on one side and 4 on the other side. The tablets should not be divided. o White opaque 75cc HDPE bottles with 38mm continuous threaded cap with pulp liners. Pack sizes: 28 tablets and 30 tablets. o 625 cc HDPE bottle with 53 mm continue threading ribbed smooth closure. Pack size: 250 tablets. Supplier and Manufacturer Hetero Labs Limited Hetero Corporate, 7-2-A2, Industrial Estates Sanath Nagar HYDERABAD 500 018, A.P., Phone: 0091-237-049-23/24/25 Fax: 91-40-23704926, 23714250 Email: contact@heterolabs.com Hetero Labs Limited Unit - III, Survey No. 51 # 22-110, IDA Jeedimetla, Qutubullapur Municipality, Ranga Reddy District, Hyderabad 500 055, India. Phone: 0091-40-23096171/72/73/74 Fax: 0091-40-23095105, 23097756, Email: contact@heterolabs.com Hetero Drugs Ltd., Unit V, Survey No. 439, 440, 441 & 458, Page 6 of 7

APIIC Formulation SEZ, Polepally Village, Jadcherla Mandal, Mahaboob Nagar, Dist - 509301, Andhra Pradesh, India For any information about this medicinal product, please contact the local representative of the supplier: Mr.M.Srinivasa Reddy Mr.I.V.S.S.Prasad Hetero Corporate Unit-III, Survey No.51 7-2-A2, Sanath Nagar #22-110, IDA, Jeedimetla, Hyderabad 500 018 Qutubullapur Muncipality, Ranga Reddy District, Phone: 0091-237-049-23/24/25 Hyderabad 500 055, Email: msreddy@heterodrugs.com Phone: 0091-40-23096171/72/73/74 <{Email:}>ivssprasad@heterodrugs.com This leaflet was last approved in April 2010. Section 6 updated in May 2016. Detailed information on this medicine is available on the World Health Organization (WHO) web site: https://extranet.who.int/prequal/ Page 7 of 7